文献速递眼底病与葡萄膜炎青光眼白内障与屈光手术

胰高血糖素样肽-1受体激动剂对慢性眼病包括年龄相关性黄斑变性的影响

Glucagon-like Peptide-1 Receptor Agonist Impact on Chronic Ocular Disease Including Age-Related Macular Degeneration.
PubMed 文献 · Ophthalmology · 2025-01-23

这项回顾性队列研究利用美国电子健康记录平台,纳入年龄>60岁且有至少5年眼科随访和用药记录的患者,比较GLP-1RA与二甲双胍、胰岛素、他汀或阿司匹林使用者的5年眼科结局。倾向匹配后,GLP-1RA与非渗出性AMD风险降低相关(对比二甲双胍HR 0.68、胰岛素HR 0.72、他汀HR 0.70),3年后该降低出现,并验证了渗出性AMD和原发性开角型青光眼风险降低,但白内障和高眼压无持续影响。

要点

  • GLP-1RA与非渗出性AMD风险降低相关,对比二甲双胍HR 0.68、胰岛素HR 0.72、他汀HR 0.70。
  • 3年后GLP-1RA对比二甲双胍HR 0.69、胰岛素HR 0.66、他汀HR 0.67,非渗出性AMD风险降低出现。
  • 3年后GLP-1RA对比胰岛素,渗出性AMD HR 0.70、原发性开角型青光眼HR 0.58。

核心结论

  • 本研究提示GLP-1RA可能降低多种年龄相关性眼病的风险,作者提出需未来前瞻性研究验证这些发现。

研究设计与样本

  • 回顾性队列研究,使用美国电子健康记录平台,纳入年龄>60岁且有至少5年眼科随访和用药记录的患者。
  • 5个用药组:GLP-1RA、二甲双胍、胰岛素、他汀或阿司匹林使用者,按人口学和慢性病风险因素进行1:1倾向匹配。
  • 主要结局为初始用药处方后5年比较白内障、高眼压、原发性开角型青光眼、非渗出性AMD和渗出性AMD,并检查5年内更早时间点。
  • 显著性定义为P<0.05且风险比(HR)阈值>1.1或<0.9。

主要发现

  • 9669例使用GLP-1RA的患者中,84.4%有糖尿病诊断,平均体重指数(BMI)为36.2 kg/m2。
  • 倾向匹配队列显示,GLP-1RA与非渗出性AMD风险降低相关:对比二甲双胍HR 0.68(95%CI 0.56-0.84)、胰岛素HR 0.72(95%CI 0.58-0.89)、他汀HR 0.70(95%CI 0.57-0.87)。
  • 该非渗出性AMD风险降低在3年后出现:对比二甲双胍HR 0.69(95%CI 0.52-0.91)、胰岛素HR 0.66(95%CI 0.5-0.87)、他汀HR 0.67(95%CI 0.51-0.88)。
  • 3年后GLP-1RA对比胰岛素,渗出性AMD风险降低(HR 0.70;95%CI 0.58-0.84),原发性开角型青光眼风险降低(HR 0.58;95%CI 0.45-0.76)。
  • GLP-1RA对比其他药物,白内障形成或高眼压风险无持续影响。

关键数值与推荐

  • 非渗出性AMD:GLP-1RA对比二甲双胍HR 0.68(95%CI 0.56-0.84),对比胰岛素HR 0.72(95%CI 0.58-0.89),对比他汀HR 0.70(95%CI 0.57-0.87)。
  • 3年后非渗出性AMD:GLP-1RA对比二甲双胍HR 0.69(95%CI 0.52-0.91),对比胰岛素HR 0.66(95%CI 0.5-0.87),对比他汀HR 0.67(95%CI 0.51-0.88)。
  • 3年后渗出性AMD:GLP-1RA对比胰岛素HR 0.70(95%CI 0.58-0.84)。
  • 3年后原发性开角型青光眼:GLP-1RA对比胰岛素HR 0.58(95%CI 0.45-0.76)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been shown to exert neuroprotective and anti-inflammatory effects across multiple organ systems. This study investigated whether GLP-1RAs influence the risk for age-related ocular diseases. DESIGN: Retrospective cohort study. PARTICIPANTS: This study used an electronic health records platform of patients in the United States. Patients > 60 years with at least 5 years of ophthalmology follow-up and medication prescription documentation were included. There were 5 medication groups: GLP-1RA, metformin, insulin, statin, or aspirin users. Cohorts were propensity matched (1:1) on demographics and chronic disease risk factors. MAIN OUTCOME MEASURES: Outcomes of cataract, ocular hypertension, primary open-angle glaucoma, nonexudative age-related macular degeneration (AMD), and exudative AMD were compared 5 years after initial medication prescription. We then examined earlier time points within the 5-year period. Significance was defined as P < 0.05 with a hazard ratio (HR) threshold of > 1.1 or < 0.9. RESULTS: Of the 9669 patients taking GLP-1RAs, 84.4% had a diagnosis of diabetes with an average body mass index (BMI) of 36.2 kg/m2. Propensity-matched cohorts demonstrated that GLP-1RAs were associated with a reduced hazard of nonexudative AMD compared with metformin (HR, 0.68; 95% CI, 0.56-0.84), insulin (HR, 0.72; 95% CI, 0.58-0.89), and statins (HR, 0.70; 95% CI, 0.57-0.87). These findings were validated compared with aspirin and in an independent older cohort of patients. This significant reduction appeared after 3 years compared with metformin (HR, 0.69; 95% CI, 0.52-0.91), insulin (HR, 0.66; 95% CI, 0.5-0.87), and statins (HR, 0.67; 95% CI, 0.51-0.88). Time course results were validated using independent cohorts of propensity-matched patients taking medications for 3 years. Notably, GLP-1RAs also significantly reduced the risk of exudative AMD (HR, 0.70; 95% CI, 0.58-0.84) and primary open-angle glaucoma (HR, 0.58; 95% CI, 0.45-0.76) compared with insulin after 3 years. Use of GLP-1RAs showed no persistent impact on the risk of cataract formation or ocular hypertension compared with other medications. CONCLUSIONS: This study suggests that GLP-1RAs may reduce the risk of multiple age-related ocular diseases and the need for future prospective studies to validate these findings. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Allan KC, Joo JH, Kim S, et al. Glucagon-like Peptide-1 Receptor Agonist Impact on Chronic Ocular Disease Including Age-Related Macular Degeneration. Ophthalmology. 2025. PMID: 39863057. doi:10.1016/j.ophtha.2025.01.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。